2 different companies with 2 sets of superstar management. One is Hep B, other is Hep C. I for one never thought they would merge. COCP's initial reverse merger foretold that.
Exactly, this. What funds like Lincoln do is sell at the market registered shares and pocket the discount negotiated with the Company. Looking at the funding agreement, the spread is 4% (unless the closing price on the date of draw down is lower, then it's the closing price). I deal with these funds all the time, standard deal. Not ideal imo, but there is no obligation for Anavex to use Lincoln until they need do. The hope is that with Nov 7th presentation, big pharma will step up after to partner with Anavex.